Currently, immunocompromised patients, who form part of the high-risk cohort are a priority group eligible for receiving novel effective COVID-19 treatments within the community following a positive test. These treatments include both antiviral drugs and neutralising monoclonal antibodies which are available via COVID Medicines Delivery Units.
The Therapeutics Clinical Review Panel has been established to review the patient cohorts which could be eligible for COVID-19 therapies. On 30 May 2022 the Department published an Independent Advisory Group report which revised the high-risk cohort and included additional groups of patients. As a result of these changes and improved identification by the National Health Service, the cohort of eligible patients has grown to an estimated 1.8 million patients in the United Kingdom.
Access to treatments could be extended further if evidence from clinical trials supports doing so. The PANORAMIC study which aims to improve understanding of the effectiveness antivirals in preventing hospitalisation and/or death in a largely vaccinated population. It will provide data for the NHS to determine which patient groups could benefit most from antiviral treatments.